Reimbursement

May 1st 2025

The Inflation Reduction Act of 2022 (IRA) drug negotiation provisions will fundamentally reshape Medicare drug pricing, provider reimbursement, and health care delivery dynamics across Part B and commercial markets, according to panelists at Asembia’s AXS25 Summit.

April 29th 2025

Experts at Asembia’s AXS25 Summit discussed the economics of specialty pharmacy for rare diseases, addressing high treatment costs and strategies for balancing innovation.

April 12th 2025

Scott A. Soefje, PharmD, MBA, BCOP, explained how the expanding use of the FDA’s 505(b)(2) drug approval pathway is creating operational and reimbursement challenges for oncology infusion centers.

January 15th 2025

Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for important specialty generic drugs to increase their profit margins.